Literature DB >> 22775237

Operationalizing treatment as prevention in Los Angeles County: antiretroviral therapy use and factors associated with unsuppressed viral load in the Ryan White system of care.

Jennifer N Sayles1, Jacqueline Rurangirwa, Min Kim, Janni Kinsler, Rangell Oruga, Mike Janson.   

Abstract

Despite extensive prevention efforts, an estimated 21% of individuals with HIV/AIDS in the United States are unaware of their status, placing them at greater risk for spreading the virus to others. HIV treatment as prevention (TasP) is rapidly becoming an important public health strategy to reduce HIV transmission at the population level. Data for this study were collected on a sample of 11,397 HIV-positive individuals in the Ryan White system, a publicly funded system of care for HIV-positive individuals in Los Angeles County who are uninsured, in 2009 to examine two components of TasP: baseline rates and factors associated with antiretroviral therapy (ART) use and viral load (VL) suppression in a publicly funded system of care. ART coverage among our sample was 90%. In multivariate analyses, those with a higher odds of having unsuppressed VL included: females compared to males (adjusted odds ratio [AOR]=1.25; 95% confidence interval [CI]=1.06, 1.47); African Americans compared to whites (AOR=1.42; 95% CI=1.24, 1.62); men who have sex with men compared to heterosexuals (AOR=1.15; 95% CI=1.00, 1.32); recent substance abusers compared to nonsubstance abusers (AOR=1.35; 95% CI=1.17, 1.55); those recently incarcerated or ever incarcerated compared to those never incarcerated (AOR=1.37; 95% CI=1.15, 1.63; and AOR=1.28; 95% CI=1.09, 1.50); and those retained in care compared to those not retained in care (AOR=1.98; 95% CI=1.76, 2.22). Understanding the key sociodemographic, geographic and behavioral factors associated with ART use as well as HIV VL suppression will be useful for informing the development and deployment of targeted programming and policies that may further enhance the implementation of the TasP approach in communities across the United States.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22775237      PMCID: PMC3407384          DOI: 10.1089/apc.2012.0097

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN: 1087-2914            Impact factor:   5.078


  26 in total

1.  Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis.

Authors:  Deborah Donnell; Jared M Baeten; James Kiarie; Katherine K Thomas; Wendy Stevens; Craig R Cohen; James McIntyre; Jairam R Lingappa; Connie Celum
Journal:  Lancet       Date:  2010-05-26       Impact factor: 79.321

2.  Disparities in outcomes for African American and Latino subjects in the Flexible Initial Retrovirus Suppressive Therapies (FIRST) trial.

Authors:  Thomas P Giordano; Glenn Bartsch; Yafeng Zhang; Ellen Tedaldi; Judith Absalon; Sharon Mannheimer; Avis Thomas; Rodger D MacArthur
Journal:  AIDS Patient Care STDS       Date:  2010-05       Impact factor: 5.078

Review 3.  The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic.

Authors:  Julio S G Montaner; Robert Hogg; Evan Wood; Thomas Kerr; Mark Tyndall; Adrian R Levy; P Richard Harrigan
Journal:  Lancet       Date:  2006-08-05       Impact factor: 79.321

4.  Universal voluntary testing and treatment for prevention of HIV transmission.

Authors:  Carl W Dieffenbach; Anthony S Fauci
Journal:  JAMA       Date:  2009-06-10       Impact factor: 56.272

5.  Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model.

Authors:  Reuben M Granich; Charles F Gilks; Christopher Dye; Kevin M De Cock; Brian G Williams
Journal:  Lancet       Date:  2008-11-27       Impact factor: 79.321

6.  Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001.

Authors:  Kelly A Gebo; John A Fleishman; Richard Conviser; Erin D Reilly; P Todd Korthuis; Richard D Moore; James Hellinger; Philip Keiser; Haya R Rubin; Lawrence Crane; Fred J Hellinger; W Christopher Mathews
Journal:  J Acquir Immune Defic Syndr       Date:  2005-01-01       Impact factor: 3.731

7.  Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings.

Authors:  Peter J Dodd; Geoff P Garnett; Timothy B Hallett
Journal:  AIDS       Date:  2010-03-13       Impact factor: 4.177

8.  Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic.

Authors:  Viviane D Lima; Karissa Johnston; Robert S Hogg; Adrian R Levy; P Richard Harrigan; Aranka Anema; Julio S G Montaner
Journal:  J Infect Dis       Date:  2008-07-01       Impact factor: 5.226

9.  The impact of incarceration upon adherence to HIV treatment among HIV-positive injection drug users: a qualitative study.

Authors:  Will Small; Evan Wood; Glenn Betteridge; Julio Montaner; Thomas Kerr
Journal:  AIDS Care       Date:  2009-06

10.  Effect of early versus deferred antiretroviral therapy for HIV on survival.

Authors:  Mari M Kitahata; Stephen J Gange; Alison G Abraham; Barry Merriman; Michael S Saag; Amy C Justice; Robert S Hogg; Steven G Deeks; Joseph J Eron; John T Brooks; Sean B Rourke; M John Gill; Ronald J Bosch; Jeffrey N Martin; Marina B Klein; Lisa P Jacobson; Benigno Rodriguez; Timothy R Sterling; Gregory D Kirk; Sonia Napravnik; Anita R Rachlis; Liviana M Calzavara; Michael A Horberg; Michael J Silverberg; Kelly A Gebo; James J Goedert; Constance A Benson; Ann C Collier; Stephen E Van Rompaey; Heidi M Crane; Rosemary G McKaig; Bryan Lau; Aimee M Freeman; Richard D Moore
Journal:  N Engl J Med       Date:  2009-04-01       Impact factor: 91.245

View more
  7 in total

1.  Early evidence from California on transitions to a reformed health insurance system for persons living with HIV/AIDS.

Authors:  Arleen A Leibowitz; Robbie Lester; Philip G Curtis; Kevin Farrell; Aaron Fox; Luke H Klipp; Jason Wise
Journal:  J Acquir Immune Defic Syndr       Date:  2013-11-01       Impact factor: 3.731

2.  Longer duration of homelessness is associated with a lower likelihood of non-detectable plasma HIV-1 RNA viral load among people who use illicit drugs in a Canadian setting.

Authors:  Jane Loh; Mary Clare Kennedy; Evan Wood; Thomas Kerr; Brandon Marshall; Surita Parashar; Julio Montaner; M-J Milloy
Journal:  AIDS Care       Date:  2016-06-01

Review 3.  Housing status and the health of people living with HIV/AIDS.

Authors:  M-J Milloy; Brandon D L Marshall; Julio Montaner; Evan Wood
Journal:  Curr HIV/AIDS Rep       Date:  2012-12       Impact factor: 5.071

Review 4.  Housing Status, Medical Care, and Health Outcomes Among People Living With HIV/AIDS: A Systematic Review.

Authors:  Angela A Aidala; Michael G Wilson; Virginia Shubert; David Gogolishvili; Jason Globerman; Sergio Rueda; Anne K Bozack; Maria Caban; Sean B Rourke
Journal:  Am J Public Health       Date:  2015-11-12       Impact factor: 9.308

5.  Unsuppressed Viral Load Level in Public Health Facilities: Nonvirological Predictors among Adult Antiretroviral Therapy Users in Southwestern Ethiopia.

Authors:  Birhanu Waju; Lamessa Dube; Muktar Ahmed; Semira Shimeles Assefa
Journal:  HIV AIDS (Auckl)       Date:  2021-05-14

Review 6.  Influence of Material Deprivation on Clinical Outcomes Among People Living with HIV in High-Income Countries: A Systematic Review and Meta-analysis.

Authors:  Vasiliki Papageorgiou; Bethan Davies; Emily Cooper; Ariana Singer; Helen Ward
Journal:  AIDS Behav       Date:  2021-12-11

7.  Factors Associated with Viral Suppression Among Racial/Ethnic Minority Women in the Miami-Dade County Ryan White Program, 2017.

Authors:  Sikeade O Caleb-Adepoju; Rahel Dawit; Semiu O Gbadamosi; Diana M Sheehan; Kristopher P Fennie; Robert A Ladner; Petra Brock; Mary Jo Trepka
Journal:  AIDS Res Hum Retroviruses       Date:  2021-07-14       Impact factor: 1.723

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.